Given that LIR‐1 binds most HLA class I molecules, this subset may be explored in both autologous and allogeneic settings to innately reject HLA class I‐ tumor cells as well as HLA class I+ target cells when combined with antitumor antibodies. This evidence concerns the gene LILRB1 and neoplasm.